BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 288 filers reported holding BIO-TECHNE CORP in Q3 2016. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $175,934,743 | +57.2% | 2,584,615 | +88.5% | 0.36% | +62.6% |
Q2 2023 | $111,914,975 | +2230.5% | 1,371,003 | +2018.1% | 0.22% | +2090.0% |
Q1 2023 | $4,802,245 | -94.8% | 64,729 | -94.2% | 0.01% | -95.2% |
Q4 2022 | $91,867,756 | -44.4% | 1,108,443 | +90.6% | 0.21% | -42.8% |
Q3 2022 | $165,126,000 | +6.3% | 581,438 | +29.8% | 0.36% | +13.1% |
Q2 2022 | $155,310,000 | +28.5% | 448,038 | +60.5% | 0.32% | +39.7% |
Q1 2022 | $120,869,000 | -59.8% | 279,117 | -51.9% | 0.23% | -58.7% |
Q4 2021 | $300,491,000 | +168.9% | 580,835 | +151.9% | 0.56% | +19.6% |
Q3 2021 | $111,752,000 | +219.1% | 230,620 | +196.5% | 0.46% | +193.7% |
Q2 2021 | $35,019,000 | -63.8% | 77,773 | -69.3% | 0.16% | -64.4% |
Q1 2021 | $96,763,000 | +17056.6% | 253,354 | +14157.4% | 0.44% | +14700.0% |
Q4 2020 | $564,000 | -91.5% | 1,777 | -93.4% | 0.00% | -93.0% |
Q3 2020 | $6,641,000 | +36.7% | 26,808 | +4.7% | 0.04% | -12.2% |
Q1 2020 | $4,857,000 | -35.6% | 25,611 | -25.4% | 0.05% | -5.8% |
Q4 2019 | $7,538,000 | -15.0% | 34,340 | -24.2% | 0.05% | -25.7% |
Q3 2019 | $8,870,000 | +14683.3% | 45,329 | +10929.0% | 0.07% | +6900.0% |
Q4 2018 | $60,000 | -99.3% | 411 | -99.1% | 0.00% | -97.4% |
Q3 2018 | $9,018,000 | +1977.9% | 44,178 | +1015.6% | 0.04% | +1166.7% |
Q3 2016 | $434,000 | -77.9% | 3,960 | -81.0% | 0.00% | -84.2% |
Q1 2016 | $1,966,000 | +612.3% | 20,796 | +577.6% | 0.02% | +533.3% |
Q4 2015 | $276,000 | -37.3% | 3,069 | -31.3% | 0.00% | -50.0% |
Q2 2015 | $440,000 | – | 4,465 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |